May 19, 2021
New data analyses from the Phase 3 ARIEL3 and ARIEL4 trials further characterize Rubraca’s efficacy and consistent safety profile in patients in the advanced ovarian cancer maintenance treatment and treatment settings BOULDER, Colo.–(BUSINESS WIRE)–$CLVS–Clovis Oncology, Inc. (NASDAQ: CLVS) today announced Read more…
